Hemophilia Management

Expert Interview

Introduction

Advisory Board

Marion Koerper, MD Professor Emerita on Recall
Department of Pediatric Hematology
School of Medicine University of California, San Francisco
(UCSF) School of Medicine
Medical Advisor
National Hemophilia Foundation

Jennifer Maahs, RN, PNP, MSN
Nurse Practitioner
Indiana Hemophilia and Thrombosis Center

Celynda G. Tadlock, PharmD, MBA
Vice President Pharmacy Business Development, Aetna
President, Coventry Prescription Management Serivces, Inc.

Hemophilia Quick Facts

  • Patients treated at a Hemophilia Treatment Center (HTC) demonstrate significantly better outcomes in terms of morbidity and mortality as a result of the HTC clinical staff experience and training, the use of guideline-based care, patient access to research protocols, and the comprehensive care model itself.
  • HTCs need to adopt well-defined metrics so payer stakeholders can evaluate standardized measures to determine the value of care delivered by HTCs. Data collection and reporting  by the HTC’s is important to develop standard care guidelines and monitor quality.

Questionnaire

Q: What best describes your primary role?

Q: Approximately how many patients with hemophilia are being managed in your organization or practice setting?

Q: Please select one topic below where additional education is needed to improve the management of patients with hemophilia within your organization. Your response will help us tailor future CE/CME programs to your specific educational needs.

Stay Connected

Join the conversation